Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and the need for new drugs is urgent. In a joint call to action, the AMR Accelerator projects ask for long-term investments, emphasizing the need to preserve the European capacity for antibiotic research and development (R&D) by sustaining the assets, expertise, and research infrastructures required to develop new treatments for drug-resistant infections.
EU capacity for antibiotic research and development requires long-term funding, say researchers
